SEC Filing Summary for Allogene Therapeutics, Inc. - Form 4 Filing

This filing details a transaction by Deborah M. Messemer, a director at Allogene Therapeutics, Inc. On June 18, 2026, Ms. Messemer was granted 95,400 Restricted Stock Units (RSUs) of the company's Common Stock. The RSUs have a transaction value of $0.00 per share. These RSUs will vest in two equal installments over one year, contingent upon continued service. Ms. Messemer currently holds 95,400 shares of Common Stock following this transaction. The filing is Form 4, indicating a change in beneficial ownership.